SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
SOPHiA GENETICS (NASDAQ: SOPH) and Element Biosciences announced a partnership on November 11, 2025 to integrate SOPHiA DDM™ AI analytics with Element's AVITI and AVITI24 sequencing systems. The collaboration aims to deliver an end-to-end NGS workflow that combines sequencing speed and multiomic capability with AI-driven variant analysis to help clinical researchers generate actionable insights more quickly.
AVITI and AVITI24 users will gain access to SOPHiA DDM applications in oncology and rare disease, enabling local genomic research with expanded analytical tools.
SOPHiA GENETICS (NASDAQ: SOPH) e Element Biosciences hanno annunciato una partnership il 11 novembre 2025 per integrare l’analisi AI di SOPHiA DDM™ con i sistemi di sequencing AVITI e AVITI24 di Element. La collaborazione mira a offrire un flusso di lavoro NGS end-to-end che combina velocità di sequencing e capacità multiomiche con l’analisi delle varianti guidata dall’IA per aiutare i ricercatori clinici a generare rapidamente intuizioni azionabili.
Gli utenti di AVITI e AVITI24 avranno accesso alle applicazioni SOPHiA DDM in oncologia e malattie rare, consentendo la ricerca genomica locale con strumenti analitici ampliati.
SOPHiA GENETICS (NASDAQ: SOPH) y Element Biosciences anunciaron una asociación el 11 de noviembre de 2025 para integrar las analizas AI de SOPHiA DDM™ con los sistemas de secuenciación AVITI y AVITI24 de Element. La colaboración tiene como objetivo ofrecer un flujo de trabajo de NGS de extremo a extremo que combine la velocidad de secuenciación y la capacidad multi-ómica con un análisis de variantes impulsado por IA para ayudar a los investigadores clínicos a generar ideas accionables más rápidamente.
Los usuarios de AVITI y AVITI24 obtendrán acceso a las aplicaciones SOPHiA DDM en oncología y enfermedades raras, lo que permitirá una investigación genómica local con herramientas analíticas ampliadas.
SOPHiA GENETICS (NASDAQ: SOPH)와 Element Biosciences는 2025년 11월 11일에 협력 관계를 발표하여 SOPHiA DDM™ AI 분석을 Element의 AVITI 및 AVITI24 시퀀싱 시스템에 통합합니다. 이 협업의 목표는 시퀀싱 속도와 다중 오믹스 기능을 AI 기반 변이 분석과 결합하여 임상 연구자가 더 빠르게 실행 가능한 통찰을 얻을 수 있도록 엔드-투-엔드 NGS 워크플로를 제공하는 것입니다.
AVITI 및 AVITI24 사용자는 종양학 및 희귀 질환 분야의 SOPHiA DDM 애플리케이션에 접근할 수 있게 되어 확장된 분석 도구와 함께 지역 유전체 연구를 가능하게 합니다.
SOPHiA GENETICS (NASDAQ: SOPH) et Element Biosciences ont annoncé un partenariat le 11 novembre 2025 pour intégrer les analyses IA de SOPHiA DDM™ aux systèmes de séquençage AVITI et AVITI24 d Element. La collaboration vise à offrir un flux de travail NGS de bout en bout qui combine la vitesse de séquençage et les capacités multiomics avec une analyse de variantes pilotée par l’IA pour aider les chercheurs cliniques à générer des informations exploitables plus rapidement.
Les utilisateurs d AVITI et AVITI24 auront accès aux applications SOPHiA DDM en oncologie et dans les maladies rares, permettant la recherche génomique locale avec des outils d’analyse élargis.
SOPHiA GENETICS (NASDAQ: SOPH) und Element Biosciences gaben am 11. November 2025 eine Partnerschaft bekannt, um die SOPHiA DDM™ AI-Analytik in Element’s AVITI- und AVITI24-Sequenzier-Systeme zu integrieren. Die Zusammenarbeit zielt darauf ab, einen end-to-end NGS-Workflow bereitzustellen, der Sequenzierungsgeschwindigkeit und Multi-Omics-Fähigkeiten mit KI-gestützter Variantenanalyse kombiniert, um klinischen Forschern schnellere umsetzbare Erkenntnisse zu ermöglichen.
ANwender von AVITI und AVITI24 erhalten Zugang zu SOPHiA DDM-Anwendungen in der Onkologie und seltenen Erkrankungen, sodass lokale genomische Forschung mit erweiterten Analysetools durchgeführt werden kann.
SOPHiA GENETICS (NASDQ: SOPH) و Element Biosciences أعلنتا عن شراكة في 11 نوفمبر 2025 لدمج تحليلات SOPHiA DDM™ AI مع أنظمة التسلسل AVITI و AVITI24 من Element. تهدف الشراكة إلى توفير سير عمل NGS متكامل يجمع بين سرعة الترميز والقدرة متعددة-omics مع تحليل المتغيرات المدعوم بالذكاء الاصطناعي لمساعدة الباحثين السريريين في توليد رؤى قابلة للتنفيذ بشكل أسرع.
سيحصل مستخدمو AVITI وAVITI24 على وصول إلى تطبيقات SOPHiA DDM في مجال الأورام والأمراض النادرة، مما يمكّن البحث الجينومي المحلي باستخدام أدوات تحليل موسَّعة.
- None.
- None.
Insights
Partnership links Element's AVITI sequencing with SOPHiA DDM™ analytics to streamline NGS research workflows.
SOPHiA GENETICS and Element Biosciences announced a collaboration on
The business mechanism is straightforward: combine a sequencing hardware stack with a validated analytics platform to reduce handoffs and technical integration work. This can shorten time-to-result for research labs that already operate AVITI systems and expand the addressable user base for SOPHiA DDM™ without requiring new sequencing investments.
Key dependencies and risks include the technical completeness of the integration, regulatory and local data-handling constraints for clinical research, and real-world validation by end users. The announcement names a reference user, Institut Paoli-Calmettes, which indicates at least one early validation site, but broader lab adoption and throughput performance remain to be demonstrated.
Concrete items to watch include deployment timelines and platform compatibility across AVITI configurations, published validation data from early adopters such as Institut Paoli-Calmettes, and availability of SOPHiA DDM™ applications on AVITI systems worldwide; expect initial signals within the next 6–12 months.
This collaboration integrates SOPHiA GENETICS' AI-powered analytics platform, SOPHiA DDM™, with Element's AVITI24™ 5D multiomic and AVITI™ sequencing systems to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS). Together, the technologies will provide speed, scalability, and flexibility, enabling clinical researchers to turn NGS data into actionable insights within a single streamlined process. AVITI and AVITI24 users will also gain access to the full suite of SOPHiA DDM™ applications in oncology and rare disease, expanding the analytical power of their sequencing workflows.
Professor Hagay Sobol, Head of the Molecular Oncogenetics Laboratory at th
e Institut Paoli-Calmettes (IPC), said: "We believe that combining the Element AVITI system with the SOPHiA DDM™ Platform has the potential to transform the way our lab approaches genomic testing by seamlessly delivering highly accurate results. We expect this collaboration that pairs SOPHiA GENETICS' powerful analytics with Element's sequencing performance will be able to deliver the consistency and scalability needed for research that helps bring precision medicine to more patients, faster." IPC is a comprehensive cancer center in
Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS , said: "Integrating our universal platform with leading sequencing technologies such as the Element AVITI system allows healthcare organizations, regardless of size or geography, to adopt innovative, AI-driven technologies while keeping genomic research local. This partnership aligns with our shared goals of democratizing access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of our respective technologies."
Molly He, CEO and Co-Founder of Element Biosciences, said: "Pairing Element's cutting-edge AVITI and AVITI24 systems with SOPHiA GENETICS' powerful AI analytics is a game-changer for the genomics community. This collaboration doesn't just streamline workflows - it redefines what's possible in sequencing, delivering richer insights, faster results and unprecedented accessibility. Together, we're breaking down barriers to enable the future of precision medicine and empower every lab, everywhere, to do more with their data."
About the technology
SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize and analyze healthcare data. Since its inception, SOPHiA GENETICS has been committed to ensuring compatibility across all technologies. Through this partnership, laboratories can process datasets of any size, retain full control of their data, and scale efficiently as precision medicine adoption accelerates worldwide.
Element Biosciences' AVITI24 5D Multiomic and AVITI next generation sequencing systems are designed to make high-performance genomics accessible to all. With its combination of accuracy, flexibility, and cost efficiency, Element empowers laboratories to scale with confidence and accelerate the researching driving precision medicine worldwide.
To learn more about the partnership or SOPHiA GENETICS, connect with the team at booth 921 at AMP in
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
About Element Biosciences, Inc.
Element Biosciences is a biology company transforming the pace and accessibility of scientific discovery. Element empowers scientists with advanced technologies that capture multiple layers of biology—from genes to proteins—delivering richer data and faster insights. Through powerful new technologies, Element is fueling research and drug discovery breakthroughs impacting diagnostic and therapeutic developments—opening the world of biology to new possibilities that improve lives everywhere. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.
SOPHiA DDM™ is for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-and-element-biosciences-unite-sequencing-power-and-ai-analytics-to-accelerate-global-research-in-precision-medicine-302610603.html
SOURCE SOPHiA GENETICS
FAQ
What did SOPHiA GENETICS (SOPH) and Element Biosciences announce on November 11, 2025?
How will the SOPH and Element partnership affect AVITI and AVITI24 users?
Does the SOPH and Element collaboration include clinical research use cases?
When and where was the SOPH and Element partnership announced?
Will the SOPH and Element integration change how labs run NGS pipelines?
Is the SOPH and Element partnership expected to expand access to precision medicine tools?
